ReviewSeminars in oncology2016
The hallmarks of premalignant conditions: a molecular basis for cancer prevention.
Review in Seminars in oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Signaling pathways and targeted interventions for precancers.Signal transduction and targeted therapy · 2026Review
- Hepatocellular Carcinoma Precursor Lesions: From Pathological Basis to Risk Stratification and Precision Intervention.Journal of hepatocellular carcinoma · 2026Review
- Targeting CDK9-dependent transcriptional addiction: a novel chemoprevention strategy for oral carcinogenesis via adenosine deaminase modulation.Cell death & disease · 2025Article
- Precision Prevention Studies: A Targeted Approach to Cancer Prevention.Cancer prevention research (Philadelphia, Pa.) · 2025Review
- Optical imaging for screening and early cancer diagnosis in low-resource settings.Nature reviews bioengineering · 2024Article
- [Multidisciplinary experts consensus on diagnosis and treatment of precancerous lesions of hepatocellular carcinoma (2023 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- Skin Inflammation Modulation via TNF-α, IL-17, and IL-12 Family Inhibitors Therapy and Cancer Control in Patients with Psoriasis.International journal of molecular sciences · 2022Article
- MicroRNA-Based Fingerprinting of Cervical Lesions and Cancer.Journal of clinical medicine · 2020Review
- Precursor and borderline lesions of the thyroid (indolent lesions of epithelial origin): from theory to practice.Gland surgery · 2020Review
- Polymorphisms in the Angiogenesis-Related GenesInternational journal of molecular sciences · 2020Article
- LGR5 in breast cancer and ductal carcinoma in situ: a diagnostic and prognostic biomarker and a therapeutic target.BMC cancer · 2020Article
- piRNAs in Gastric Cancer: A New Approach Towards Translational Research.International journal of molecular sciences · 2020Review
- [Expert consensus on multidisciplinary diagnosis and treatment of precancerous lesions of hepatocellular carcinoma (2020 edition)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020Article
- Effects of Nicotinamide on Cervical Cancer-Derived Fibroblasts: Evidence for Therapeutic Potential.Cancer management and research · 2020Article
- The landscape of early carcinogenesis revealed through the lens of integrative genomics, epigenomics, and transcriptomics.Journal of thoracic disease · 2019Article
- In silico learning of tumor evolution through mutational time series.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Human β-Defensin 2 Expression in Oral Epithelium: Potential Therapeutic Targets in Oral Lichen Planus.International journal of molecular sciences · 2019Article
- Reduced CD8Clinical oral investigations · 2019Article
- The genetic basis of disease.Essays in biochemistry · 2018Review
- Somatic mutations in benign breast disease tissue and risk of subsequent invasive breast cancer.British journal of cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The hallmarks of premalignant lesions were first described in the 1970s, a time when relatively little was known about the molecular underpinnings of cancer. Yet it was clear there must be opportunities to intervene early in carcinogenesis. A vast array of molecular information has since been uncovered, with much of this stemming from studies of existing cancer or cancer models. Here, examples of how an understanding of cancer biology has informed cancer prevention studies are highlighted and emerging areas that may have implications for the field of cancer prevention research are described. A note of caution accompanies these examples, in that while there are similarities, there are also fundamental differences between the biology of premalignant lesions or premalignant conditions and invasive cancer. These differences must be kept in mind, and indeed leveraged, when exploring potential cancer prevention measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.